Delivering live biotherapeutics orally remains one of the challenges in microbiome therapy.
In this white paper, Evonik presents a real-world case study of how EUDRACAP® Select—a ready-to-fill enteric capsule—enabled the safe and targeted delivery of a full fecal microbiota ecosystem in patients with acute myeloid leukemia.
Developed in collaboration with MaaT Pharma, the capsule was tested under simulated gastrointestinal conditions and validated in a Phase 1b clinical trial. The results showed improved microbiota engraftment and richness, reduced development complexity, and accelerated clinical readiness.
Download the white paper to find out more: